NCT00496548View on ClinicalTrials.gov

Urinary Prostaglandin E Metabolite (PGE-M), A Metabolite of Prostaglandin E2 (PGE2): A Novel Biomarker of Crohn's Disease Activity

NACompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Crohn's Disease
Interventions
PROCEDURE

Fecal calprotectin

Fecal calprotectin levels obtained and compared to urinary PGE-M and serum C-reactive protein (CRP) levels.

PROCEDURE

Urinary PGE-M Level

Urinary PGE-M level obtained and compared to fecal calprotectin and serum CRP levels.

Trial Locations (1)

37232-2285

GI Clinical Research; Vanderbilt University Medical Center, Nashville

Sponsors

Collaborators (1)

UCB Pharma
All Listed Sponsors
collaborator

UCB Pharma

INDUSTRY

lead

Vanderbilt University Medical Center

OTHER